Rituximab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00073 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 12 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | follicular lymphoma | KG + DL |
| 2 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | KG + DL |
| 3 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | KG + DL |
| 4 | metastatic neoplasm | KG + DL |
| 5 | malignant spiradenoma | KG + DL |
| 6 | neoplasm of mature B-cells | KG + DL |
| 7 | small intestinal Burkitt lymphoma | KG + DL |
| 8 | small intestinal mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 9 | thyroid gland mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 10 | breast mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 11 | tonsillar lymphoma | KG + DL |
| 12 | follicular lymphoma, susceptibility to, 1 | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.